Farmas USA

Ahaa, Gracias Mugi 

Que bien , espero esa sea el final de la t bajista que hemos visto e incio de la alcista tambien

Parece que estaba del lado correcto mi analisis, dificil eso en bolsa, anima dar en  el blanco 1 de 100.,

Creo que lo posteó Ana días atrás, ayer comenzó la presentación de los pósters.

http://ir.advaxis.com/press-release/financial-news/advaxis-announces-four-poster-presentations-highlighting-lm-based

En ST hace algunos días que la intentan pumpear con rumores de BO por parte de Amgen, poco creibles.

ADXS

MLNT

Que presentaban cosas a partir del 21 en ECCMID ya se sabía, lo comentó Ana hace unos días, lo que no sabíamos era el qué, ni que fueran 12 presentaciones! Luego habrá que ver de esas 12 si hay algo destacable. No sé si habrá abstracts en abierto antes.

ACAD

Abstract AACR

http://www.abstractsonline.com/pp8/#!/4562/presentation/10717

Novel anti-psychotic drug for pancreatic cancer treatment

Specialty Report On Infectious Disease: Unlocking The Upcoming Binary Event Of Achaogen And Value Of Melinta

Summary

Achaogen already posted robust phase 3 data for plazomicin (non-inferiority and superiority) as a treatment for resistant infection. The PDUFA date of plazomicin was set for June 25, 2018.

Melinta recently merged with Cempra to improve its cash position for the launch of four antibiotics (three of which were in-licensed from a large partner).

Despite the southbound trading for infectious disease innovators, there is a good chance of a trend reversal for Achaogen and Melinta stocks.

https://seekingalpha.com/article/4163118-specialty-report-infectious-disease-unlocking-upcoming-binary-event-achaogen-value-melinta

---

La presentacion sera en Madrid 

Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that a total of 12 presentations are planned at the upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting April 21-14, 2018 in Madrid, Spain.

--

Ana te pagamos los gastos y nos los cuentas toooooooo.?

MLNT

MLNT

Bueno, en este caso creo que lo sabíamos yo y vosotros, pero el mercado más bien no. No era algo que se hubiera publicado ni comentado. Yo lo saqué/deduje de una de sus últimas presentaciones. Debería reflejarse al alza.

DVAX

Esta es otra que hemos dejado de cometar por aqui pero que en el medio-largo plazo si sigue teniendo God News de SD-101 y consigue un buen partner para agilizar las ventas mundiales de HEPLISAV se va a  ir mas lejos de los que podamos imaginar, y ahora si que veo mas probabiliadedes de BO,.. bueno asi lo veo yo.. claro

----------

Investors bullish on early-stage data on Dynavax's SD-101 + Keytruda in advanced melanoma; shares up 14% premarket

Apr. 16, 2018 7:58 AM ET|About:  Dynavax Technologies C... (DVAX)|By:  Douglas W. House, SA News Editor 

Merck's announcement of positive Phase 3 results for KEYTRUDA (pembrolizumab) in late-stage melanoma has stoked modest premarket buying in Dynavax Technologies (NASDAQ: DVAX). Shares are up 14% on light volume.

Tomorrow, April 17,  data from a Phase 1b study assessing the combination of lead candidate SD-101 and pembrolizumab in advanced melanoma will be presented.

Previously:  Merck's Keytruda shows treatment benefit in late-stage study in advanced melanoma; shares up 1% premarket (April 16)

Previously:  Combination of Dynavax's SD-101 and Keytruda show 100% response in melanoma study; shares ahead 4% after hours (June 2, 2017)

https://seekingalpha.com/news/3345732-investors-bullish-early-stage-data-dynavaxs-sdminus-101-keytruda-advanced-melanoma-shares-14?app=1&uprof=37

Dynavax SD-101: Right Drug In The Wrong Combo

https://seekingalpha.com/article/4163184-dynavax-sdminus-101-right-drug-wrong-combo?li_source=LI&li_medium=liftigniter-widget

MLNT

Era algo público, se dijo en la presentación de resultados de 2017, en las preguntas de los analistas a la directiva. Dejo la conversación ya que viene a cuento:

Sue Cammarata

There have been a number of abstracts that have already been presented and there will be a few more that will be out this year at ECCMID that have been accepted. We also anticipate that the TANGO-2 data will be published this year. We of course would like to discuss this with the FDA, so we have a planned engagement to discuss potential path forward.

Kevin DeGeeter

Terrific. And you mentioned ECCMID. Could you just provide us a general recap as to what we should be looking for in ECCMID in addition to some granularity on TANGO-2?

Dan Wechsler

So let me have Erin start on ECCMID because a lot of our presentations are discovery stuff, right. So Erin can provide a little bit of ECCMID color and some of the posters and then Sue continue on.

Erin Duffy

I think at ECCMID certainly there will be a number of posters and one oral presentation on our novel pyrrolocytosine class. In addition to that, there are a number of abstracts both on Baxdela and on Vabomere.

https://seekingalpha.com/article/4156056-melinta-therapeutics-mlnt-ceo-dan-wechsler-q4-2017-results-earnings-call-transcript?page=7

Tras 25 semanas consecutivas en rojo ... MACD semanal de CELG ha iniciado verde ... esperemos que aguante ...

no es mucho ... pero es un cambio ...